Orum Ascending High Mountain Of Undruggable RAS Protein
Emerging Company Profile: Orum Therapeutics is aiming to develop a first-in-class therapeutic antibody for cancer and other intractable diseases, using its unique cell-penetrating antibody platform. Following a successful Series A financing, the young South Korean biotech’s next big milestone is to enter clinical trials by 2019 with its first program in oncology, targeting activated RAS protein.
You may also be interested in...
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.